Four RCTs were included in the review (n=1,725 patients). All trials satisfied all the quality criteria, except for blinding details; although all the trials used blinded assessors, other blinding details were not specified. Follow-up periods ranged from six to nine months.
Cilostazol was associated with a significantly decreased incidence of in-segment restenosis (OR 0.51, 95% CI 0.38 to 0.68; I2=0%; four RCTs), and an increased minimum luminal diameter (WMD 0.16, 95% CI 0.10 to 0.22; four RCTs) for both drug-eluting and bare-metal stents (and also when analysed individually).
Rates of target vessel revascularisation (OR 0.45, 95% CI 0.25 to 0.83; I2=0%; two RCTs) and late lumen loss (WMD -0.14, 95% CI -0.2 to -0.07; two RCTs) were decreased significantly only in the drug-eluting stent group taking triple therapy.
Rates of major adverse cardiac and/or cerebrovascular events, stent thrombosis and bleeding were not significantly different between groups.
The funnel plot suggested the possibility of publication bias could not be ruled out.